Antimicrobial resistance (AMR)

AI clinical trials concept
#Antimicrobial resistance (AMR) #Artificial intelligence (AI) #Google #Imperial College London

AI co-scientist could supercharge science, say researchers

A complex problem that took scientists a decade to explain was solved in just two days by a new artificial intelligence (AI) tool, the BBC has reported.  Professor José Penadés and his team at from the Imperial College London Department of Infectious Disease had spent 10 years… Read More

#News #Trending News

#Antimicrobial resistance (AMR) #Bacteria #Funding #Gram-negative bacteria #Infex Therapeutics

£1m grant for drug targeting multi-drug-resistant bacteria

Infex Therapeutics, in collaboration with Justus-Liebig-University Giessen (JLU), Germany, has been awarded a £1 million grant from PACE (Pathways to Antimicrobial Clinical Efficacy).  The company plans to develop a first-in-class BamA inhibitor targeting multi-drug-resistant (MDR) Gram-negative pathogens.  BamA inhibitors are an entirely new class of antimicrobial drug designed to target… Read More

#Business & Investment #News

Bacteria in Petri dishes
#Antibiotics #Antimicrobial resistance (AMR) #Cystic fibrosis #Funding #Glox Therapeutics #LifeArc

Glox awarded share of £3m cystic fibrosis funding

Glox Therapeutics has been awarded a share of the £3 ($3.6) million funding from the Collaborative Discovery Programme (CDP), launched by the Cystic Fibrosis Antimicrobial Resistance (CF AMR) Syndicate with funding from LifeArc.   Glox Therapeutics will receive up to £500,000 of the fund to accelerate the development of its precision… Read More

#Business & Investment #News

Thermo Fisher Scientific
#Antimicrobial resistance (AMR) #Antimicrobials #Bacteria #Webinar

Structural advances in multidrug-resistant Acinetobacter baumannii

In a recent DDW event, sponsored by Thermo Fisher Scientific, Daniel J Klein, Senior Director of Protein and Structural Chemistry at Merck and Co discussed the current advancements taking place in antibiotic drug discovery. Klein spoke about how structural biology tools such as cryoelectron microscopy and X-ray crystallography are being used… Read More

#Exclusive Content

GBP pound sterling funding
#Antibiotic resistance #Antimicrobial resistance (AMR) #Financing #Funding #Glox Therapeutics

£1 million PACE grant to accelerate precision antibiotics 

Glox Therapeutics has secured £1 million in grant funding from Pathways to Antimicrobial Clinical Efficacy (PACE), one of the UK’s largest public-private initiatives targeting early-stage antimicrobial medicines and diagnostic discovery.   The funding will help to accelerate the development of Glox Therapeutics’ novel antibiotics targeting drug-resistant pathogenic bacteria, Escherichia coli… Read More

#Business & Investment #News

Hydrogel
#Antibiotic resistance #Antibiotics #Antimicrobial resistance (AMR) #Bacteria #Chalmers University of Technology #Hydrogel

Hydrogel enhances antibiotics’ effect against resistant bacteria

New research has shown that resistant bacteria can regain susceptibility to antibiotics when the treatment is combined with a material equipped with antibacterial peptides. The study, performed in a laboratory environment, shows that antibiotics can achieve a 64-fold increase in bactericidal effect when used together with… Read More

#News #Trending News

Acinetobacter baumannii
#Antibiotic resistance #Antimicrobial resistance (AMR) #Bacteriophage #Phage therapy

Superbug map supports ‘off-the-shelf’ region-specific phage therapies

Scientists have created a global ‘superbug map’ for one of the most dangerous superbug species, Acinetobacter baumannii, which will aid the development of lifesaving bacteriophage (phage) therapies. In a paper published in the journal Cell, an international collaboration led by scientists at the… Read More

#News

Antibiotics
#Antibiotic resistance #Antibiotics #Antimicrobial resistance (AMR) #Immunology / Virology & Vaccines #World Health Organization

Better use of vaccines will reduce AMR deaths, report finds

Vaccines against 24 pathogens could reduce the number of antibiotics needed by 22% every year, according to a new report by the World Health Organization (WHO). While some of these vaccines are already available but underused, others would need to be developed and brought to the… Read More

#News #Trending News

Destruction of a bacterium by silver nanoparticles.
#Antibiotic resistance #Antimicrobial resistance (AMR) #Bacteria #EVŌQ Nano #Nanopharmaceutics

Silver nanoparticle destroys bacteria from the inside

New data indicates EVŌQ Nano’s nanoparticle EVQ-218 could combat the world’s worst superbugs without triggering antimicrobial resistance (AMR). Bacteria’s ability to form biofilms is a key factor in their resistance to antibiotics. Biofilms are protective layers that shield bacteria from therapeutic interventions and… Read More

#Editor's Choice #News

#Antimicrobial resistance (AMR) #Cystic fibrosis #Funding #LifeArc #Medicines Discovery Catapult (MDC)

£3m accelerates new drugs for lung infections in cystic fibrosis

The Cystic Fibrosis Antimicrobial Resistance (CF AMR) Syndicate has announced the first cohort of drug discovery projects to receive its Collaborative Discovery Programme (CDP) funding. The £3 ($3.9) million programme, funded by LifeArc, will support six early-stage novel antimicrobial projects over two years to accelerate new treatments for lung infections… Read More

#Business & Investment #News

Antibiotics
#ABPI #Antibiotics #Antimicrobial resistance (AMR) #Antivirals #United Nations #WHO

Access to medicines vital in tackling AMR, world leaders agree

Global leaders have approved a plan to reduce the estimated 4.95 million human deaths associated with bacterial antimicrobial resistance (AMR) annually by 10% by 2030. The political declaration was agreed at the 79th United Nations General Assembly (UNGA) High-Level Meeting on Antimicrobial Resistance (AMR). Read More

#News #Trending News

Bacteria in Petri dishes
#Antibiotic resistance #Antibiotics #Antimicrobial resistance (AMR) #Bacteria #The University of Manchester

New understanding of bacteria mutation rates could combat AMR

Scientists have discovered a way to control mutation rates in bacteria, introducing the possibility of new strategies to combat antimicrobial resistance (AMR). The researchers used high-performance computing to simulate more than 8,000 years of bacterial evolution, allowing scientists to predict mechanisms that control mutation rates. Read More

#Editor's Choice #News

Bacteria in Petri dishes
#Antibiotics #Antimicrobial resistance (AMR) #Drug discovery #Japan #UK

UK-Japan partnership to tackle antimicrobial resistance

Two experts in infectious disease have been selected to be policy fellows as part of a wider Japan-UK collaboration to tackle the growing crisis of antimicrobial resistance (AMR). AMR is a major threat to global health and was responsible for 1.27 million deaths in 2019 alone. Read More

#News

Gut microbiome
#Antibiotics #Antimicrobial resistance (AMR) #Gram-negative bacteria #Gut microbiome #University of Illinois

Antibiotic kills gram-negative bacteria, spares gut microbiome

Researchers have developed a new antibiotic that reduced or eliminated drug-resistant bacterial infections in mouse models of acute pneumonia and sepsis while sparing healthy microbes in the gut. The drug, called lolamicin, also warded off secondary infections with Clostridioides difficile, and was effective against more than… Read More

#News #Trending News

#Antibiotic resistance #Antibiotics #Antimicrobial resistance (AMR) #Interview

Why more work is needed to fight antimicrobial resistance

Reece Armstrong speaks to Professor Janet Hemingway CBE about current efforts in tackling antimicrobial resistance. The threat of AMR has been well documented in recent years. Perhaps the most notable effort came from the 2014 report “The Review on Antimicrobial Resistance” which was chaired by Lord Jim O’Neill and which… Read More

#Exclusive Content

Bacteria in Petri dishes
#Antibiotic resistance #Antibiotics #Antimicrobial resistance (AMR) #GSK #Phase III trial

GSK announces positive data for gonorrhoea antibiotic

Positive results have been announced by GSK for its antibiotic targeting uncomplicated urogenital gonorrhoea (GC) in adolescents and adults. First results from the EAGLE-1 Phase III trial for gepotidacin show that two oral doses of the antibiotic displayed superior success rates (92.6%) when compared to the… Read More

#Editor's Choice #News